Request samples now to start patients in the clinic on INVEGA SUSTENNA®
The INVEGA SUSTENNA® Outpatient Sample Program is designed to provide you with samples of the product free of charge to help you in initiating patients on
INVEGA SUSTENNA®. The Outpatient Sample Program is also available for inpatient facilities that prefer to receive samples instead of free trial units. Through the program, you will receive initiation doses of INVEGA SUSTENNA® by mail, sent directly to your facility.
Returning User? Please Sign In
Email Address:
Forgot Your Password?
Need Help? Call 1-855-463-1912
To Inactivate Your eResource Center Account, Click Here ►

   * Indicates Required Field

  * First Name     * Professional Designation
  * Last Name     * State License Number
Mobile Phone     * State of Licensure


  * Email Address     * Security Question #1
  * Re-enter Email     * Security Answer #1
  * Create a Password     * Security Question #2
  * Re-enter password     * Security Answer #2
           * Security Question #3
           * Security Answer #3

Please review the terms and conditions required for eSampling. Please accept the following terms and conditions in order to participate in this program.
  * I agree that I am creating an electronic signature binding under the Prescription Drug Marketing Act of 1987. I understand that this electronic signature is the legal and binding equivalent of my handwritten signature.
  * I certify that I am a licensed practitioner eligible to receive and prescribe these samples. If I am a Nurse Practitioner or Physician Assistant, I certify that I am authorized and eligible in the state within which I am currently practicing to request and receive these samples and that I have my supervising Physician’s approval to do so.
  * I certify that I treat patients with schizophrenia and schizoaffective disorder 18 years of age and older.
  * My signature on this request certifies that I recognize that this is a product sample for the needs of my patients and will not be sold, traded, bartered, returned for credit or for third party reimbursement.
  * I agree to have processes in place to avoid selling, bartering, returning for credit or billing for sampled goods and to train employees on these processes, including the fact that such conduct is illegal.
  * I agree to take precautions to safeguard my email account against unauthorized access, disclosure, alteration, and destruction.
  * I agree that my password and security answers are confidential, and that all the information that I have provided is true. I am 18 years of age or older.
  * By providing your information, you are requesting to register your participation in the INVEGA SUSTENNA® Sampling Program where your information will be used to satisfy this purpose and to fulfill any optional requests you may have indicated. Your information will be shared by Janssen Pharmaceuticals, Inc. with their affiliates and third parties involved in the INVEGA SUSTENNA® Sample Program and for fulfillment of your optional requests. At any time, you can request to be removed from participating in the INVEGA SUSTENNA® Sample Program and any options you selected by calling 1-855-463-1912. All information you provide will be governed by our Privacy Policy, which is located at the bottom of the page. By providing us your information and clicking on the below SUBMIT REQUEST button, you have read, understand, and agree to these conditions.
  Yes, I would like to receive information about mental health products, programs, and services from Janssen Pharmaceuticals, Inc., including information about INVEGA SUSTENNA®.


INVEGA SUSTENNA® (paliperidone palmitate) is indicated for the treatment of:

Schizophrenia in adults.
Schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers or antidepressants in adults.



See full Prescribing Information for complete Boxed Warning.

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. INVEGA SUSTENNA® is not approved for use in patients with dementia-related psychosis.

INVEGA SUSTENNA® is contraindicated in patients with a known hypersensitivity to either paliperidone, risperidone, or to any excipients of the INVEGA SUSTENNA® formulation.

Cerebrovascular Adverse Reactions: Cerebrovascular adverse reactions (e.g., stroke, transient ischemic attacks), including fatalities, were reported at a higher incidence in elderly patients with dementia-related psychosis taking risperidone, aripiprazole, and olanzapine compared to placebo. No studies have been conducted with oral paliperidone, INVEGA SUSTENNA®, or the 3-month paliperidone palmitate extended-release injectable suspension in elderly patients with dementia. These medicines are not approved for the treatment of patients with dementia-related psychosis.

Neuroleptic Malignant Syndrome (NMS): NMS, a potentially fatal symptom complex, has been reported with the use of antipsychotic medications, including paliperidone. Clinical manifestations include muscle rigidity, fever, altered mental status, and evidence of autonomic instability (see full Prescribing Information). Management should include immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, intensive symptomatic treatment and close medical monitoring, and treatment of any concomitant serious medical problems.

QT Prolongation: Paliperidone causes a modest increase in the corrected QT (QTc) interval. Avoid the use of drugs that also increase QTc interval and in patients with risk factors for prolonged QTc interval. Paliperidone should also be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias. Certain circumstances may increase the risk of the occurrence of torsades de pointes and/or sudden death in association with the use of drugs that prolong the QTc interval.

Tardive Dyskinesia (TD): TD is a syndrome of potentially irreversible, involuntary, dyskinetic movements that may develop in patients treated with antipsychotic medications. The risk of developing TD and the likelihood that dyskinetic movements will become irreversible are believed to increase with duration of treatment and total cumulative dose, but can develop after relatively brief treatment at low doses. Elderly female patients appeared to be at increased risk for TD, although it is impossible to predict which patients will develop the syndrome. Prescribing should be consistent with the need to minimize the risk of TD (see full Prescribing Information). Discontinue drug if clinically appropriate. The syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn.

Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and body weight gain. While all of the drugs in the class have been shown to produce some metabolic changes, each drug has its own specific risk profile.

Hyperglycemia and Diabetes Mellitus: Hyperglycemia and diabetes mellitus, in some cases extreme and associated with ketoacidosis, hyperosmolar coma or death have been reported in patients treated with all atypical antipsychotics (APS). Patients starting treatment with APS who have or are at risk for diabetes mellitus should undergo fasting blood glucose testing at the beginning of and during treatment. Patients who develop symptoms of hyperglycemia during treatment should also undergo fasting blood glucose testing. All patients treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia. Some patients require continuation of antidiabetic treatment despite discontinuation of the suspect drug.

Dyslipidemia: Undesirable alterations have been observed in patients treated with atypical antipsychotics.

Weight Gain: Weight gain has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.

Orthostatic Hypotension and Syncope: INVEGA SUSTENNA® may induce orthostatic hypotension in some patients due to its alpha-adrenergic blocking activity. INVEGA SUSTENNA® should be used with caution in patients with known cardiovascular disease, cerebrovascular disease or conditions that would predispose patients to hypotension (e.g., dehydration, hypovolemia, treatment with antihypertensive medications). Monitoring should be considered in patients for whom this may be of concern.

Falls: Somnolence, postural hypotension, motor and sensory instability have been reported with the use of antipsychotics, including INVEGA SUSTENNA®, which may lead to falls and, consequently, fractures or other fall-related injuries. For patients, particularly the elderly, with diseases, conditions, or medications that could exacerbate these effects, assess the risk of falls when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic therapy.

Leukopenia, Neutropenia and Agranulocytosis have been reported with antipsychotics, including INVEGA SUSTENNA®. In patients with a history of clinically significant low white blood cell count (WBC)/absolute neutrophil count (ANC) or drug-induced leukopenia/neutropenia, perform a complete blood count frequently during the first few months of therapy. Consider discontinuing INVEGA SUSTENNA® at the first sign of a clinically significant decline in WBC in the absence of other causative factors. Monitor patients with clinically significant neutropenia for fever or other symptoms or signs of infection and treat promptly if such symptoms or signs occur. Discontinue INVEGA SUSTENNA® in patients with severe neutropenia (absolute neutrophil count <1000/mm3) and follow their WBC until recovery.

Hyperprolactinemia: As with other drugs that antagonize dopamine D2 receptors, INVEGA SUSTENNA® elevates prolactin levels and the elevation persists during chronic administration. Paliperidone has a prolactin-elevating effect similar to risperidone, which is associated with higher levels of prolactin elevation than other antipsychotic agents.

Potential for Cognitive and Motor Impairment: Somnolence, sedation, and dizziness were reported as adverse reactions in subjects treated with INVEGA SUSTENNA®. INVEGA SUSTENNA® has the potential to impair judgment, thinking, or motor skills. Patients should be cautioned about performing activities that require mental alertness such as operating hazardous machinery, including motor vehicles, until they are reasonably certain that INVEGA SUSTENNA® does not adversely affect them.

Seizures: INVEGA SUSTENNA® should be used cautiously in patients with a history of seizures or with conditions that potentially lower seizure threshold. Conditions that lower seizure threshold may be more prevalent in patients 65 years or older.

Administration: For intramuscular injection only by a healthcare professional using only the needles provided in the INVEGA SUSTENNA® kit. Care should be taken to avoid inadvertent injection into a blood vessel.

Drug Interactions: Strong CYP3A4/P-glycoprotein (P-gp) inducers: Avoid using a strong inducer of CYP3A4 and/or P-gp (e.g. carbamazepine, rifampin, St. John’s Wort) during a dosing interval for INVEGA SUSTENNA®. If administering a strong inducer is necessary, consider managing the patient using paliperidone extended-release tablets.

Pregnancy/Nursing: INVEGA SUSTENNA® may cause extrapyramidal and/or withdrawal symptoms in neonates with third trimester exposure. Advise patients to notify their healthcare professional if they become pregnant or intend to become pregnant during treatment with INVEGA SUSTENNA®. Patients should be advised that there is a pregnancy registry that monitors outcomes in women exposed to INVEGA SUSTENNA® during pregnancy. INVEGA SUSTENNA® can pass into human breast milk. The benefits of breastfeeding should be considered along with the mother's clinical need for INVEGA SUSTENNA® and any potential adverse effects on the breastfed infant from INVEGA SUSTENNA® or the mother's underlying condition.

Commonly Observed Adverse Reactions for INVEGA SUSTENNA®: The most common adverse reactions in clinical trials in patients with schizophrenia (≥5% and twice placebo) were injection site reactions, somnolence/sedation, dizziness, akathisia and extrapyramidal disorder. No adverse events occurred at a rate of ≥5% and twice placebo during the 15-month double-blind, placebo-controlled study in patients with schizoaffective disorder. The following adverse reactions occurred more frequently (a ≥2% difference vs. placebo) in the long-term study in patients with schizoaffective disorder: weight increased, nasopharyngitis, headache, hyperprolactinemia, and pyrexia.


Please click here to read the full Prescribing Information, including Boxed WARNING, for INVEGA SUSTENNA®.

This page was last modified on: 10/12/2018 at 12:55 ET

© Janssen Pharmaceuticals, Inc., 2018. All rights reserved.
Your use of the information on this site is subject to the terms of our Legal Notice. Please see our Privacy Policy

This site is published by Janssen Pharmaceuticals, Inc., which is solely responsible for its contents. This information is intended for the use of our healthcare professionals in the United States only. Janssen Pharmaceuticals, Inc., recognizes that the Internet is a global communications medium; however, laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here may not be appropriate for use outside the United States including Puerto Rico.

Capitalized product names are trademarks of Janssen Pharmaceuticals, Inc.

Some documents on this site are stored in Adobe PDF format and require the free Adobe® Reader® to view.